SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: A positive correlation was found in patients with chronic myeloid leukemia (CML) in a phase II trial between survival and the functional activity of OCT1 that was assessed by measuring imatinib influx [63,64].